TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02148952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WHO Safe Childbirth Checklist Program
Description: The IHF group will receive the WHO Safe Childbirth Checklist Program designed to maximize likelihood of effective and sustained uptake of the program by birth attendants in the designated facilities. The program includes three key implementation steps that involve: engagement of leadership and clinicians at the state, district, and local levels, a formal launch to introduce the Checklist, and support through peer coaching and data feedback. The intervention facilities will also receive a standardized maternity register to ensure appropriate data collection.
Study: NCT00348738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Administration of 10.000 I.U Erythropoeitin SQ 3x/week, two weeks prior to radiation therapy until a haemoglobin concentration of \>14g/dl, \<15g/dl is reached or until the end of the radiation therapy.
Study: NCT03357796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005
Description: 80 mg, oral tablets, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005
Description: 80 mg, oral tablets, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pristiq
Description: 50 mg, oral tablets, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pristiq
Description: 50 mg, oral tablets, single dose
Study: NCT03286543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPRINT Beta System
Description: The SPRINT Beta System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT Beta System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Beta Stimulator).
Study: NCT03829462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: regorafenib tab 40 mg i.e 160 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: regorafenib tab 40 mg i.e 160 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: irinotecan 120 mg/m2 cycle 1, 150 mg/m2 cycle 2, 180 mg/m2 cycle 3 and more
Study: NCT04522882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actimetry
Description: Actimetry will be performed at home to measure physical activity, sleep duration and patient chronotype for 7 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patients will complete food and medication intake questionnaires for 7 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose level and insulin administration
Description: Continuous subcutaneous glucose level (measured by continuous glucose monitor (CGM)) and the insulin doses delivered by the insulin pump will be collected for 7 days .
Study: NCT03217669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat tablet: 100mg or 300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Sirolimus tablet: 1mg, 2mg, 3mg, or 6mg
Study: NCT03592173

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Paired TMS & Peripheral Nerve Stimulation
Description: Method of assessing neurophysiology and activity of the spinal cord

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Paired TMS & Peripheral Nerve Stimulation
Description: Method of assessing neurophysiology and activity of the spinal cord

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Paired TMS & Peripheral Nerve Stimulation
Description: Method of assessing neurophysiology and activity of the spinal cord
Study: NCT04009824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-v PLUS Vaccine
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-v PLUS Vaccine
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-v PLUS Vaccine
Description: Administered by subcutaneous injection
Study: NCT03217669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Sirolimus tablet: 1mg, 2mg, 3mg, or 6mg
Study: NCT01503970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arthroscopic matrix encapsulated chondrocyte implantation
Description: Each implant of collagen scaffold contains approximately 6,000,000 autologous chondrocytes. This constructs of 10 mm diameter are implanted arthroscopically at the defect.
Study: NCT04009824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-v PLUS Vaccine
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51 Adjuvant
Description: Administered by subcutaneous injection
Study: NCT03928574

Intervention type: PROCEDURE
Intervention: Ultrasound-Guided Plane Block
Description: Ultrasound-Guided Plane Block Medial Brachial Cutaneous and the Intercostobrachial Nerves

Intervention type: PROCEDURE
Intervention: Conventional Block
Description: Conventional Block Medial Brachial Cutaneous and the Intercostobrachial Nerves
Study: NCT01369797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specific intervention
Description: Patients included in the specific intervention group will benefit from a personalized action plan presented in a multidisciplinary staff that will be established according to the detected frailties. In follow up visits, a new evaluation will be done and the action plan reviewed.
Study: NCT03063372

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomella pomegranate extract
Description: Participants will take a 500 mg capsule of pomegranate extract twice daily for 28 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take a gelatin placebo twice daily for 28 days.
Study: NCT01125384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional swabbing
Description: physician swabs patient's throat according to standard rules before referral of the patient to throat swabbing by nurse.
Study: NCT02030392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Cognitive-behavioral intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control group
Description: Education and information
Study: NCT01937559

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Description: 1.5g of TXA in 100ml normal saline solution

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid (TXA)
Description: 1.5g of TXA in 100ml normal saline solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study: NCT01828281

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: All subjects will undergo ultrasound examination of the abdomen the day after overnight polysomnography (PSG) and then at 3 months after completion of therapeutic or subtherapeutic CPAP treatment of 4 cm water.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CPAP
Description: All subjects will undergo ultrasound examination of the abdomen the day after overnight polysomnography (PSG) and then at 3 months after completion of therapeutic or subtherapeutic CPAP treatment of 4 cm water.
Study: NCT03089450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGBio stent
Description: Percutaneous Coronary Intervention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biomatrix flex
Description: Percutaneous Coronary Intervention
Study: NCT01476371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based group treatment
Description: An 8-week course of mindfulness-based group treatment (one 2-hour session per week; 10 patients per group). Each group session will be led by two mindfulness instructors, who will lead the patients through the Here \& Now mindfulness program. Between sessions, patients will perform additional mindfulness practice at home via the Internet.
Study: NCT02775162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normothermic Machine Perfusion (NMP)

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (Ice)
Study: NCT03287661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-based Behavioural Therapy
Description: The treatment program is an eight module (8-week) ABBT for chronic pain. The online treatment material is administered via the WebCAPSI Therapy program. This online program allows participants to progress through the treatment modules at their own pace. Each module is designed to cover a specific component of ABBT and will facilitate understanding of the components through audio files, veteran, military and RCMP-specific vignettes, text-based material, and homework exercises/assignments. Each module is designed to be completed in 60 minutes or less. On the completion of each module, and facilitated through the WebCAPSI Therapy program, the participants are asked to complete a homework exercise to which they answer questions previously encountered throughout the module. The principle therapist responds to each homework exercise within 24-hours of its online submission.
Study: NCT02911441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Study: NCT03956628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stay safe program
Description: Prevention consist of 5-6 lessons having topics about learning safety skills which includes identifying touch, safe and unsafe environment/events, bullying, the good or bad secrets and strangers.
Study: NCT02509156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allo-MSCs
Description: 20 transendocardial injections of 0.4ml allo-MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 transendocardial injections of 0.4ml Buminate solution administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
Study: NCT01679860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT
Description: Clin A:~* CHOP-Campath (CHOP-C) for 2 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO on days +1 to +5; Campath-1H (alemtuzumab) dose escalation 3-10-20mg IV days - 2, - 1, 0 (first CHOP-C) or 30mg SC day 0 (second CHOP-C). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on days + 1 and 21 (first and second CHOP-C).~* HYPER-C-HiDAM for 2 cycles: Methotrexate 1.5gr/m2 day +1; Cyclophosphamide 300mg/m2 every 12 hours days +2-3-4; ARA-C 2gr/m2 every 12 hours days +2-3-4; G-CSF 5μcg/kg/day starting from day +5 until peripheral blood stem cell harvest~* Myeloablative regimen followed by autologous transplantation or Reduced intensity conditioning followed by allogeneic transplantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clin B (CHOP- CAMPATH) Chemo-immunotherapy
Description: Clin B:~* CHOP-Campath (CHOP-C) for 6 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO from day +1 to day +5¸ Campath-1H (alemtuzumab) 3-10mg IV on days - 1 and 0 ( first CHOP-C course) or 10mg SC on day 0 (for the following 5 C-CHOP courses). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on day +1 of each CHOP-C course.
Study: NCT02547649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114-A
Description: Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).
Study: NCT04009824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51 Adjuvant
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alhydrogel® Adjuvant
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: Administered by subcutaneous injection
Study: NCT01047462

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery for acute perforated diverticulitis
Description: Primary resection vs laparoscopic lavage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery for acute perforated diverticulitis
Description: Primary resection vs laparoscopic lavage
Study: NCT01768702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of C3BS-CQR-1
Description: Injection of the C3BS-CQR-1 using the C-Cath® injection catheter.
Study: NCT02547649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114-B
Description: Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13®
Description: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), and 6B (4.4 mcg) in each 0.5 mL dose.
Study: NCT03604146

Intervention type: BEHAVIORAL
Intervention: Medical quality control intervention strategy
Description: Training and education for diagnosis, treatment and management of COPD for doctors and nurses; Regular inspection and supervision of medical quality
Study: NCT03347851

Intervention type: OTHER
Intervention: MRI
Description: Enrolled patients will complete a non-contrast cardiac MRI

Intervention type: OTHER
Intervention: MRI
Description: Enrolled patients will complete a non-contrast cardiac MRI
Study: NCT01768702

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Sham, no injection
Description: Mimic the injection procedure trough insertion of a sham catheter. No injection actually performed
Study: NCT03148899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin Intranasal Spray
Description: In human volunteers intranasal administration of oxytocin significantly increases parasympathetic and decreases sympathetic cardiac control. In addition to the classic effects of oxytocin on uterine contraction and milk ejection, recent work indicates oxytocin is present in both males and females and has an important role in both behavior and cardiovascular homeostasis, particularly during anxiety and stress.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin Intranasal Spray
Description: In human volunteers intranasal administration of oxytocin significantly increases parasympathetic and decreases sympathetic cardiac control. In addition to the classic effects of oxytocin on uterine contraction and milk ejection, recent work indicates oxytocin is present in both males and females and has an important role in both behavior and cardiovascular homeostasis, particularly during anxiety and stress.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Intranasal Spray
Description: The placebo has been compounded to be an inactive, blinded comparative to the oxytocin nasal spray.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Intranasal Spray
Description: The placebo has been compounded to be an inactive, blinded comparative to the oxytocin nasal spray.
Study: NCT03347851

Intervention type: OTHER
Intervention: Transthoracic echocardiography exam
Description: Enrolled patients will complete a transthoracic echocardiography exam.

Intervention type: OTHER
Intervention: Transthoracic echocardiography exam
Description: Enrolled patients will complete a transthoracic echocardiography exam.
Study: NCT04611373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide Levamisole
Description: Acetazolamide tablet 25mg/ tablet, 2 tablets a day Levamisole 25mg/ tablet, 6 tablets/day Continue treatment until the disease progresses
Study: NCT02828462

Intervention type: OTHER
Intervention: CAPRI
Study: NCT02114918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Modification Program
Description: Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral word. Thus, although there will be no specific instruction to direct attention away from the threat word, on all trials, the position of the neutral word will indicate the position of the probe.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control Condition
Description: Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm is not intended to facilitate an attention bias away from threatening material. In this case, the probe randomly replaces the threat or neutral word.
Study: NCT03704090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention
Description: Prevention of postoperative delirium by occupational therapy intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard non-pharmacological prevention intervention
Description: Prevention of postoperative delirium using standard non-pharmacological prevention measures

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard non-pharmacological prevention intervention
Description: Prevention of postoperative delirium using standard non-pharmacological prevention measures
Study: NCT00218569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01588951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine consolidation
Description: Cytarabine-based consolidation per institutional standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine consolidation
Description: Cytarabine-based consolidation per institutional standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic transplant
Description: Allogeneic stem cell transplant per institutional standards.
Study: NCT00124254

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Silicone metacarpophalangeal joint arthroplasty
Description: Intervention involves reconstructing the metacarpophalangeal joint using the Swanson silastic implant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Non-surgical usual care
Study: NCT00736463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: One arm of randomized crossover

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80 mg
Description: Second arm of randomized crossover
Study: NCT00467272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: 6 mg/kg IV every 24 hours for at least 7-14 days, depending on the type of bacteria. Treatment expected to be at least 14 days for SA and at least 7 days for enterococci and CNS, Corynebacterium, and Propionibacterium.
Study: NCT04198922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04100538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health coach
Description: The health-coaching program includes (1) my file, (2) lesson, (3) self-assessment, and (4) interaction modules. My file allows participants recording their disease history. The lesson includes knowledge of fibromyalgia, stress and relaxation, emotion and positive thinking, sleep hygiene, communication skills, and exercise. The self-assessments includes symptom diary, exercise and general diary. The interaction encourages participants interacting with peers and the health coach. Participants can share practical advices, strategies, real-life examples or questions via texts or photos in share garden. Participants can connect to the health coach via contact with health coach. The coach will provide comments or responses approximately 10-30 min for each time. The coach will monitor each participant's lesson list and attendance for each lesson. The health coach will also guide the participants to create their own tailored programs according to participants' predominant symptom subtypes.
Study: NCT01640067

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Neural Stem Cells
Description: Surgical microinjection of human neural stem cells on spinal cord of ALS patients
Study: NCT00404742

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX211
Description: 0.2 mg/kg, twice a day (BID)
Study: NCT01271049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Food Product
Description: Novel food product containing essential oil blend

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Food Product
Description: Control food product
Study: NCT00414973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Subcutaneous, 20 micrograms/day, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmon Calcitonin
Description: Intranasal, 200 International Units (IU)/day, 24 weeks
Study: NCT02240524

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy
Description: The dissected lymph nodes were classified according to the Japanese Classification of Gastric Carcinoma, first English edition.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: D2 lymphadenectomy
Description: The dissected lymph nodes were classified according to the Japanese Classification of Gastric Carcinoma, first English edition.